Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial
| Autor: | Ch. Christofillakis, Antonia Kalykaki, John Souglakos, N. Vardakis, D. Mavroudis, A. Kotsakis, V. Georgoulias, Sophia Agelaki, Lambros Vamvakas, E. Tselepatiotis, A. Argiraki, Athanasios G. Pallis |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Pulmonary and Respiratory Medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Docetaxel Stable Disease Gefitinib Maintenance therapy Internal medicine Carcinoma Non-Small-Cell Lung Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Metastasis neoplasms Aged business.industry Smoking Middle Aged medicine.disease Rash Chemotherapy regimen Survival Analysis Toxicity Quinazolines Female Taxoids medicine.symptom business Progressive disease medicine.drug |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 55(1) |
| ISSN: | 0169-5002 |
| Popis: | Summary Purpose To evaluate the activity and toxicity of the sequential administration of docetaxel followed by gefitinib in patients with advanced non-small cell lung cancer (NSCLC). Patients and treatment Forty-one patients pre-treated with at least one prior chemotherapy regimen (platinum- or taxane-based) for advanced/metastatic NSCLC received three cycles of docetaxel 30mg/m 2 , administered as a 1-h IV infusion, on days 1, 8 and 15 of each 4-week cycle followed by gefitinib 250mg daily po. Gefitinib treatment was continued until disease progression, development of unacceptable toxicity, or withdrawal of patients consent. Results Two (4.9%) patients achieved a partial response and 10 (24.4%) stable disease, for a disease control rate of 29.3% (95% CI: 15.3%–43.2%) while on weekly docetaxel treatment. Additionally, progressive disease (PD) was observed in 29 (70.7%). No objective responses were observed during the gefitinib maintenance therapy; however, 17 (41.5%) patients presented stable disease maintained for more than 2 months. Median time to progression was 3.0 months (range: 1–38.3 months; 95% CI: 2.4–3.6); median overall survival 6.9 months (range: 1.2–40.2 months; 95% CI: 5.34–8.52) while the 1-year survival was 28.8%. Therapy was generally well tolerated with diarrhea and rash being the most frequent toxicities. Conclusions The sequential administration of docetaxel and gefitinib was well tolerated and moderately active against advanced pre-treated NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect